Active substanceSulfacetamideSulfacetamide
Similar drugsTo uncover
  • Sulfacetamide
    drops d / eye 
    ESKOM NPK, OAO     Russia
  • Sulfacil sodium
    drops d / eye 
    UPDATE OF PFC, CJSC     Russia
  • Sulfacil sodium (Albucide)
    drops d / eye 
    LEKKO, ZAO     Russia
  • Sulfacil sodium-Vial
    drops d / eye 
    ALVILS, LTD.     Russia
  • Sulfacil sodium-DIA
    drops d / eye 
  • Sulfacil sodium-SOLOfarm
    drops d / eye 
    GROTEKS, LLC     Russia
  • Sulfacil sodium
    drops d / eye 
  • Sulfacil sodium
    drops d / eye 
    FARMAK, PAO     Ukraine
  • Sulfacil sodium
    drops d / eye 
    SYNTHESIS, OJSC     Russia
  • Sulfacil sodium
    drops d / eye 
    VIPS-MED, LLC     Russia
  • Sulfacil sodium
    drops d / eye 
  • Sulfacil sodium
    drops d / eye 
    YUZHFARM, LLC     Russia
  • Sulfacil sodium
    drops d / eye 
  • Sulfacil-sodium-MEZ
    drops d / eye 
  • Dosage form: & nbspEye drops.
    Composition:
    1 ml of the solution contains sodium sulfacetamide monohydrate (sodium sulfacyl) 200 mg in terms of 100% substance;

    Excipients: sodium thiosulfate 1 mg; hydrochloric acid solution of 1 M to pH 8; water for injection up to 1 ml.
    Description:Transparent colorless or slightly yellowish liquid.
    Pharmacotherapeutic group:Antimicrobial agent - sulfonamide.
    ATX: & nbsp

    A.07.A.B   Sulfonamides

    Pharmacodynamics:Sulfacil sodium has a bacteriostatic effect against gram-positive and gram-negative bacteria - streptococci, pneumococci, gonococci, E. coli, chlamydia, actinomycetes. The mechanism of action of the drug is due to competitive antagonism with para-aminobenzoic acid (PABA) and inhibition of dihydropteroate synthetase, which leads to a disruption in the synthesis of tetrahydrofolic acid necessary for the synthesis of purine and pyrimidine bases. As a result, the synthesis of nucleic acids (DNA and RNA) of bacterial cells is disrupted.
    Pharmacokinetics:
    Penetrates into the tissue of the eye, where it exerts its specific antibacterial effect. Acts mainly locally, but part of the drug is absorbed through the inflamed conjunctiva and enters the systemic circulation.
    When topically applied, the maximum concentration (Cmax) of sulfonamides in the cornea (about 3 mg / ml), the anterior chamber humidity (about 0.5 mg / ml) and the iris (about 0.1 mg / ml) is reached 30 min after instillation.A small amount (less than 0.5 mg / ml) of sulfacetamide is retained in the tissues of the eyeball for 3-4 hours. If the epithelium of the cornea is damaged, the penetration of sulfonamides is enhanced.
    Indications:As part of complex therapy for children and adults for the treatment of conjunctivitis, blepharitis, purulent corneal ulcer; adults for the treatment of chlamydial and gonorrheal diseases of the eyes. For the prevention and treatment of neonatal blennery.
    Contraindications:Hypersensitivity to the drug components and sulfanilamides in the anamnesis.
    Pregnancy and lactation:There is insufficient experience in the use of the drug during pregnancy or lactation. It is possible to use sulfacetamide to treat pregnant women and nursing mothers as prescribed by the attending physician if the intended benefit to the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:
    Adults and children. Bury 1-2 drops of the drug in each conjunctival sac 4-6 times a day.
    For prevention of blenarea in newborns. Bury 2 drops of the drug in each conjunctival sac immediately after birth and 2 drops in 2 hours.
    Side effects:Local allergic reactions, short-term burning, blurred vision, lacrimation, itching, itching in the eyes.
    Overdose:
    Not described.

    Interaction:Sulfacetamide enhances the effect of anticoagulants of indirect action. Combined use with novocaine, dicain, procaine, tetracaine, anesthesin reduces the bacteriostatic effect of sulfacetamide. Diphenin, PASK, salicylates increase its toxicity. Sulfacetamide incompatible with the salts of silver.
    Special instructions:In patients with increased sensitivity to furosemide, thiazide diuretics (hydrochlorothiazide), sulfonylurea derivatives (glibenclamide), inhibitors of carbonic anhydrase (diacarb), there may be a cross-sensitivity to sulfacetamide.
    Effect on the ability to drive transp. cf. and fur:In connection with the possibility of side effects (lacrimation, blurred vision) after the use of the drug should refrain from driving or working with complex mechanisms.
    Form release / dosage:Eye drops 20%.
    Packaging:For 5 ml or 10 ml in polyethylene bottles, ukuporennye caps.Each bottle, along with instructions for medical use, is put in a pack of cardboard.
    Storage conditions:Store in a dark place at a temperature of 8 to 15 ° C. Keep out of the reach of children.
    Shelf life:
    2 years. After opening the vial the drug is suitable for 28 days. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:П N015815 / 01
    Date of registration:26.05.2009
    The owner of the registration certificate:FARMAK, PAO FARMAK, PAO Ukraine
    Manufacturer: & nbsp
    Representation: & nbspFARMAK PAOFARMAK PAO
    Information update date: & nbsp03.09.2015
    Illustrated instructions
      Instructions
      Up